Adult haemophagocytic syndrome.

By M. Ramos-Casals, P. Brito-Zerón, A. López-Guillermo, M. Khamashta, X. Bosch. The Lancet, 2014

1,254 citations recorded by the source corpus.

Subfields: Hematology, Immunology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/0258c650b55302b15ebaa5ae4299062e3b297914

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. Daniel G. Tenen

In Immunology

1. Miriam Merad
2. B. Rollins
3. Daniel G. Tenen

Citations in the corpus

• Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. (2017, neutral): “Hypertriglyceridemia‡ 221 (65) 118 (35) 30 (8)”
• Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. (2019, methodology): “8,10 Currently, there are no accepted classi fi cation criteria for adult MAS-HLH.”
• Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment (2020, background): “Given that genetic factors also play a role in primary HLH/MAS cases, a meta-analysis was performed to analyze both the countries where HLH/MAS cases are frequently reported and where the frequency of severe and lethal COVID-19 infections are high [38].”
• Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak (2020, background): “Patients with hematologic cancer in our study include patients with leukemia, myeloma, and lymphoma, who have a more compromised immune system than patients with solid tumors (11).”
• Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy (2020, neutral): “The laboratory hallmarks of sHLH are cytopenia, elevated levels of ferritin, transaminases, triglycerides, lactate dehydrogenase (LDH) and D-Dimer, and low fibrinogen [9].”
• Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions (2020, neutral): “Such a cytokine profile is strongly reminiscent of both Cytokine Release Syndrome (CRS, seen in CAR T cell therapy) and hemophagocytic lymphohistiocytosis (HLH) [76,77].”
• Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. (2016, background): “Secondary HLH may occur at any age, and the first clinical symptoms are usually associatedwith an infectious episode, rheumatic condition, ormalignancy.(92) The clinical coursemay be severe, and the mortality is still significant.”